<i>N</i> ‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trial

Abstract

This pilot study suggests that NAC safely improves lupus disease activity by blocking mTOR in T lymphocytes.